Antifungal Innate Immunity: A Perspective from the Last 10 Years

Fabián Salazar  Gordon D. Brown

Medical Research Council Centre for Medical Mycology at the University of Aberdeen, Aberdeen Fungal Group, Institute of Medical Sciences, Aberdeen, UK

Keywords
Antifungal immunity · Fungal pathogens · Pathogenesis

Abstract
Fungal pathogens can rarely cause diseases in immunocompetent individuals. However, commensal and normally non-pathogenic environmental fungi can cause life-threatening infections in immunocompromised individuals. Over the last few decades, there has been a huge increase in the incidence of invasive opportunistic fungal infections along with a worrying increase in antifungal drug resistance. As a consequence, research focused on understanding the molecular and cellular basis of antifungal immunity has expanded tremendously in the last few years. This review will provide an overview of the most exciting recent advances in innate antifungal immunity, discoveries that are helping to pave the way for the development of new strategies that are desperately needed to combat these devastating diseases.

Introduction
The complex interaction between host and microbe is particularly reflected in the pathogenesis of fungal diseases. Most fungi are ubiquitous in the environment, and our immune system has co-evolved and adapted to their presence over millions of years. Fungi can colonize almost every niche within the human body. Certain fungi, such as Candida albicans are commensal, whereas others, such as Aspergillus fumigatus, are environmental opportunists, which can cause devastating invasive diseases when immune homeostasis is disrupted. In fact, fungi are associated with an extensive variety of diseases in mammals, ranging from cutaneous lesions and acute self-limiting pulmonary manifestations in immunocompetent individuals to inflammatory diseases and severe life-threatening infections in immunocompromised patients. Over 3 million people acquire life-threatening invasive fungal infections every year. Opportunistic invasive fungal infections are a significant cause of morbidity and mortality in immunocompromised individuals, and their occurrence has increased dramatically as a result of modern immunosuppressive medical interventions and HIV/AIDS. Our armamentarium to combat these infections is limited, and there is an urgent need to develop more effective antifungal drugs and vaccines. In addition, we need improved methods of diagnosis for optimal management of these infections.

Ten years ago, fungal immunology research was largely focused on defining the molecular interactions between pathogen-associated molecular patterns (PAMPs) and their cognate pattern recognition receptors (PRRs),
and we were beginning to understand how immune cells could interact with fungi as some of the molecules involved in fungal recognition were discovered. Dendritic cells (DCs) were found to act at different levels in the immune response against fungi. They were not only able to mount an immediate innate immune response by producing inflammatory mediators, they could also influence subsequent adaptive immune responses, including tolerance to commensal organisms. This model has moved DCs to the center stage in many fields, including fungal infections, as promising targets for immunotherapeutic intervention. These cellular and molecular studies lead to the conclusion that understanding the initial stages of how innate immune responses are activated will result in the construction of better vaccines and immunomodulatory strategies effective at eliciting protective immunity against fungi.

The discoveries in the last 10 years have been particularly exciting. The identification of mutations or polymorphisms in patients as well as the development and use of knockout mouse models has substantially enhanced our understanding of the underlying mechanisms and functions of numerous PRRs in antifungal immunity in areas such as intracellular signaling, induction and/or regulation of cellular responses, and shaping of adaptive immunity. Novel myeloid and lymphoid-derived cell subsets have been discovered and their roles in antifungal immunity determined. In this review, we will cover the most exciting advances in innate antifungal immunity that have occurred over the last decade, with a specific focus on PRRs and the cells involved. We will also provide a brief overview of how our expanded understanding is being translated into novel therapeutic approaches.

**PRRs in Fungal Recognition**

Sensing of fungal-associated molecular patterns such as cell wall constituents (i.e., carbohydrate polymers and glycoproteins) and intracellular components (i.e., DNA) relies on the expression of a plethora of PRRs in immune and nonimmune cells. After recognition, PRRs can mediate various cellular functions, from fungal uptake and killing to the production of cytokines and chemokines, which could influence the resultant immune responses.

Great advances have been made in our understanding of how fungi interact with the immune system. The discovery of Toll-like receptors (TLR) as key receptors in immunity, followed by the identification of dectin-1 as a β-glucan receptor, paved the way to the discovery of new receptors involved in fungal recognition and their subsequent cellular responses. In addition, we have gained new insights into their signaling pathways, mechanisms of regulation as well as crosstalk communication. PRRs can be classified into several families based on their structure and function, including the C-type lectin receptors (CLRs), TLRs, nucleotide binding and oligomerization domain (NOD)-like receptors (NLRs), and retinoic acid-inducible gene (RIG)-like receptors (RLRs), which will be discussed in the sections below.

**C-Type Lectin Receptors**

CLRs comprise a superfamily of proteins that can recognize diverse self and nonself molecules, and thus CLRs can regulate a wide range of physiological and pathological processes. They are constituted of soluble and membrane-bound proteins characterized by the presence of at least 1 C-type lectin domain (CTLD), some of which act as carbohydrate recognition domains (CRD). Conserved residues in the CRD allow recognition of diverse sugar structures, including the EPN (Glu-Pro-Asn) and QPD (Gln-Pro-Asp) motifs which confer specificity for mannose and galactose, respectively. However, other CTLDs lack these components and can recognize a broader range of ligands, including protein and lipids. Structurally, most membrane-bound CLRs consist of a cytoplasmic tail, a transmembrane region, and at least 1 CTLD in the extracellular domain. Others have multiple CTLDs, such as the mannose receptor (MR), which has 8 extracellular CTLDs.

Fungal cell walls contain numerous glycans, glycolipids, and glycoproteins that are not found in mammals, and these structures are recognized by several CLRs discussed in the sections below.

**Dectin-1**

Dectin-1 (clec7a), also known as the β-glucan receptor – as it was first described – is the best-characterized receptor involved in antifungal immunity. It is a type II transmembrane protein that can recognize β-1,3-glucans in the cell wall of diverse pathogenic fungi in a Ca²⁺-independent manner. Expression of dectin-1 was originally thought to be primarily restricted to myeloid cells, including DCs, monocytes, macrophages, and neutrophils, although human B cells and subsets of T cells also express
this receptor [1]. More recently, expression of dectin-1 has been described in human mast cells, keratinocytes, and epithelial cells [2–4].

Intracellular Signaling

Signaling from dectin-1 is known to involve the immunoreceptor tyrosine-based activation motif (ITAM)-containing cytoplasmic domain, which is phosphorylated by a Src family kinase allowing the recruitment of the Syk kinase leading to several cellular responses, described below [1]. Subsequent studies led to the identification of caspase-associated recruitment domain 9 (CARD9) as a key downstream transducer of dectin-1 and other CLR signaling. The Syk pathway leads to activation of a molecular scaffold composed of CARD9, Bcl10, and MALT1, through PKCδ, culminating in the recruitment of several transcription factors, including the NF-κB [5]. Signaling via dectin-1 has shown to induce additional intracellular pathways, including the Raf-1 kinase pathway, and the canonical (NLRP3/caspase 1) and noncanonical (MALT1/caspase 8) inflammasomes [6]. In the last few years, great advances have been made in understanding the mechanisms that regulate dectin-1 signaling (Fig. 1). Recently, 3 complementary studies showed that the E3 ubiquitin ligase CBLB targets dectin-1, dectin-2, macrophage C-type lectin (MCL) (described in more detail below), and their adapter molecule Syk for degradation, and thus exerts a strong anti-inflammatory effect [7–9]. The authors showed that treatment strategies involving the inhibition of CBLB led to increased inflammatory responses and improved the outcome of experimental candidiasis, which provides evidence that CBLB might represent a therapeutic target in fungal disease. Furthermore, it has been found that another ubiquitin ligase TRIM62 as well as Vav proteins regulate CARD9-mediated antifungal immunity, and these molecules are also potential therapeutic targets [10, 11]. Vav proteins are key activators of

![Diagram of dectin-1 signaling pathway](image-url)
the CARD9 pathway by cooperating downstream of dectin-1 to engage CARD9 for NF-κB control and pro-inflammatory gene transcription, while TRIM62 acts as a CARD9-binding partner facilitating CARD9 polyubquitination, which is essential for its activity. Moreover, TRIM62— as well as Vav1/2/3-deficient mice exhibit extreme susceptibility to Candida infection, suggesting that they have a pivotal role in antifungal immunity [10, 11]. Interestingly, CD23, a novel CLR, which is well known for its function as a low-affinity receptor for IgE, plays an important role in antifungal immunity through recognition of surface components of fungal pathogens, such as α-mannan and β-glucan, leading to upregulation of nitric oxide synthase (NOS2) expression, reactive oxygen species (ROS) production, and fungal killing. JNK1 was shown to negatively regulate CD23 expression through dectin-1-induced NFAT activation, modulating its antifungal role. Importantly, treatment with 2 different JNK inhibitors significantly increased survival of C. albicans-infected mice, suggesting their potential use as a novel antifungal therapy (Fig. 1) [12].

Recent studies have shown that monocytes and macrophages can promote lymphocyte-independent protection during systemic Candida reinfection (and provide protection against other nonfungal infections) via epigenetic reprogramming at the level of histone H3 methylation resulting in a phenomenon known as innate immunological memory or trained immunity. In particular, β-glucan induces trained immunity in monocytes via a dectin-1/Raf-1/Akt/mTOR/HIF-1α pathway associated with switching glucose metabolism from oxidative phosphorylation to aerobic glycolysis, which defines a novel therapeutic approach for both infectious and inflammatory diseases [13].

**Cellular Responses**

After ligand binding, dectin-1 can induce several cellular responses, including phagocytosis, respiratory burst, and chemokine and cytokine production [1]. Recent advances have also given us considerable new insights into the cellular functions that are regulated by dectin-1. For instance, it has been shown that dectin-1 can negatively regulate fungal-mediated neutrophil extracellular trap (NET) formation, and dectin-1 deficiency promotes NET-mediated pathology. Mechanistically, phagocytosis mediated via dectin-1 acts as a cellular sensor for microbial size, preventing NETosis by downregulating neutrophil elastase translocation to the nucleus. Upon contact with noningestible pathogens, dectin-1-deficient mice succumb to the infection due to their increased levels of NETosis leading to tissue damage, and treatment with a neutrophil elastase inhibitor could rescue these mice [14]. Dectin-1 has also been implicated in autophagy since signaling through dectin-1 can trigger the recruitment of autophagy-related protein light chain 3 (LC3) to phagosomes containing β-1,3-glucan, which can facilitate MHC-II presentation of fungal-derived antigens [15, 16].

**Role in Antifungal Immunity**

The most compelling evidence in the last years comes from mouse models, in which absence of this receptor leads to different degrees of susceptibility to infection with many pathogenic fungi including C. albicans, A. fumigatus, and Pneumocystis carinii, and more recently Candida glabrata, Trichophyton rubrum, and Coccidiodes immitis. In these models, dectin-1 was required for fungal recognition and killing by myeloid cells, and subsequent development of T-helper cell-mediated adaptive immune responses and susceptibility was associated with impaired leukocyte responses and inflammatory cell recruitment resulting in increased fungal growth and dissemination [17, 18]. In addition to protection against systemic fungal disease, dectin-1 has a crucial role in protecting the gastrointestinal (GI) tract during systemic candidiasis and in inflammatory bowel disease, and has been shown to modulate gut homeostasis by interacting with fungal components of the microbiota, which will be further discussed in the following section. In addition, dectin-1 and intestinal fungi have recently been linked with the development of alcoholic liver disease. Chronic alcohol administration causes fungal dysbiosis and translocation of fungal β-glucan into the systemic circulation, which induces liver inflammation and alcoholic liver disease in a dectin-1/IL-1β-dependent manner [19]. All these data highlight the crucial role of dectin-1 in modulating fungal-mediated inflammation.

In humans, single nucleotide polymorphisms (SNPs) in dectin-1 have also been linked with increased susceptibility to major fungal infections, including mucosal candidiasis and invasive aspergillosis. The mutated form of dectin-1 (Y238X), showing reduced expression, did not mediate β-glucan binding and was associated with defective cytokine production [20, 21]. Moreover, an SNP in dectin-1 has also been associated with a severe form of ulcerative colitis [22], highlighting the role of dectin-1 in gut homeostasis, as described.
The Dectin-2 Cluster

Research in the last 10 years has also seen the discovery and characterization of a new cluster of CLRs involved in antifungal immunity. The genes encoding these receptors are located in a cluster, near dectin-1, on chromosome 6 in mice and chromosome 12 in humans, and members of this family include clec6a (dectin-2), clec4d (MCL), and clec4e (macrophage-inducible C-type lectin or Mincle), amongst others (which have not yet been implicated in antifungal immunity). Their expression appears to be primarily restricted to myeloid cells, including monocytes, macrophages, neutrophils, and DCs [23].

Ligands and Cellular Responses

Dectin-2 – the prototypical member of this family – contains 1 CRD in the extracellular domain that can recognize α-mannans and O-linked mannoproteins from several fungi, including Candida, Histoplasma capsulatum, and Cryptococcus neoformans, in a Ca²⁺-dependent manner. This interaction can modulate cytokine and ROS production, as well as fungal killing [24]. In addition, dectin-2 can induce cysteinyl leukotriene production, which has been shown to be essential for the initiation of airway inflammation and Th2 immunity against house dust mites. Interestingly, it also mediates cysteinyl leukotriene production following recognition of A. fumigatus, which could have implications in fungal-mediated asthma exacerbations [25]. MCL has been mainly associated with the recognition of α-mannans from Candida, while Mincle, originally described as the receptor for the mycobacterial cell wall glycolipid trehalose-6,6′-dimycolate (TDM), can also interact with mannitol-linked mannosyl fatty acids, glyceroglycolipids, and α-mannose from Malassezia leading to cytokine production. More recently, the interaction between Mincle and its newly identified intracellular ligand β-glucosylceramide (GlcCer) was involved in the pathogenesis of Gaucher disease, an inflammatory genetic disorder characterized by the hematopoietic-specific deletion of the degrading enzyme of GlcCer, named glucosylceramidase. Accumulation of GlcCer in specific organs, including the liver and spleen, induces proinflammatory cytokine production and systemic inflammation in a Mincle-dependent manner [26].

Intracellular Signaling

All the receptors of this family couple with the ITAM-containing Fc receptor γ-chain (FcRγ) chain to drive intracellular signaling via the Syk-CARD9 pathway [27]. Signaling through these receptors can often synergize or antagonize that of other CLRs, including dectin-1, TLRs, and inflammasomes [28]. MCL can dimerize with either dectin-2 or Mincle modulating their surface expression and magnifying their signaling activation and subsequent cellular responses, and these interactions will be reviewed in the section below [29, 30].

Role in Antifungal Immunity

In vivo, dectin-2 has been shown to exert a protective role against C. albicans, C. glabrata, and T. rubrum infections [31] and, together with MCL, have been suggested to promote Th17 responses to Fonsecaea pedrosoi and Blastomyces dermatitidis, respectively [32, 33], while Mincle can antagonize these responses [32]. Mice deficient in MCL show impaired vaccine resistance against B. dermatitidis infections, and this lack of resistance was associated with a reduced recruitment of Th17 cells to the lung upon recall following experimental challenge [33]. Recent studies, using deficient mouse models, have suggested that Mincle might play a role in host defense during infections with Pneumocystis spp. (pneumonia), C. albicans, and Malassezia. In these models, Mincle deficiency was associated with altered cytokine responses and increased susceptibility to infection [34–36].

In humans, it has been shown in a small cohort of patients that a dectin-2 SNP is associated with susceptibility to pulmonary cryptococcosis [37]. MCL and Mincle have not been linked yet with susceptibility to fungal infections in humans, although SNPs have been associated with other diseases, such as tuberculosis and rheumatoid arthritis.

DC-Specific Intercellular Adhesion Molecule-3-Grabbing Nonintegrin

DC-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) is a type II transmembrane human receptor whose expression is restricted to myeloid cells, including macrophages and DCs [38]. There are 8 murine homologs of DC-SIGN, known as SIGNR, and all of these are located in a gene cluster within chromosome 8.

Ligands and Intracellular Signaling

DC-SIGN forms tetramers with each chain containing 1 extracellular CRD that binds mannosylated and fucosylated structures. The receptor possesses an incomplete ITAM in its cytoplasmic tail that is not thought to be able to directly induce cellular responses. Rather, upon

Antifungal Innate Immunity

J Innate Immun 2018;10:373–397
DOI: 10.1159/000488539
ligand recognition, signaling from DC-SIGN modulates other signaling pathways, including signals induced from TLRs. For instance, in immature DCs, the cytoplasmic tail of DC-SIGN is bound by the adaptor protein LSP1 and the Raf-1 signalosome, consisting of CNK1, KSR1, and Raf-1. Upon recognition of mannose-containing pathogens, such as *C. albicans*, various proteins are recruited to the signalosome that induce Raf-1 activation, which then results in the phosphorylation and acetylation of the NF-κB subunit p65. p65-p50 complexes are also simultaneously activated by TLRs. Acetylated p65 is more stable and has an enhanced transcriptional rate which leads to an increased activation of its target genes, promoting Th1 and Th17 differentiation. On the other hand, following recognition of fucose-containing pathogens, such as *Schistosoma mansoni*, the Raf-1 signalosome is displaced. LSP1 becomes phosphorylated and enables the assembly of the fucose-specific signalosome consisting of the kinase IKKz and the deubiquitinase CYLD that allows nuclear translocation of ubiquitinated Bcl3. Nuclear Bcl3 then modulates TLR-induced cytokine and chemokine expression profiles to promote Th2 responses [38]. Thus DC-SIGN is able to direct adaptive immune responses based on the nature of the pathogen.

**Role in Antifungal Immunity**

Due to the absence of in vivo models, most research on DC-SIGN in the last decade has relied on in vitro studies. In addition to its role in the recognition of mannanproteins from *C. albicans*, it has also been suggested to interact with polysaccharides from *Paracoccidioides* extracellular vesicles and to mediate internalization of *Aspergillus* conidia [24, 39]. SIGNR3, the closest murine homolog of DC-SIGN, has been implicated in sensing fungi present in the microbiota [40]. However, more studies are needed to explore the role of these receptors in an in vivo context.

In a small cohort of patients, it was suggested that SNPs of DC-SIGN are correlated with the development of invasive pulmonary aspergillosis and fungal keratitis. Although these results need to be validated in larger cohorts, they suggest that genetic variants of DC-SIGN could influence the risk of developing fungal infections [17].

**Mannose Receptor**

MR is a type-I transmembrane protein primarily expressed by myeloid cells, including macrophages and DCs, but is also expressed by epithelial and endothelial cells. The extracellular domain of MR consists of 3 regions: a cysteine-rich domain, a fibronectin type II-like domain, and 8 CRDs. The intracellular domain contains a short cytoplasmic tail that lacks any defined signaling motif.

**Ligands and Cellular Responses**

MR has 2 lectin binding activities involving Ca$^{2+}$-dependent recognition of carbohydrates terminated in D-mannose, L-fucose, or N-acetyl glucosamine via its CRDs, and Ca$^{2+}$-independent binding of sulfated acidic glycans through its cysteine-rich domain. MR was the first receptor described to be involved in the recognition of fungi, including *C. albicans*, *C. neoformans*, and *P. carinii*, and shown to be able to induce their phagocytosis by DCs [23]. However, some authors have suggested that MR is more a binding receptor that requires a partner to trigger phagocytosis in myeloid cells [41]. Later, *C. albicans* was shown to induce IL-17 production from human antigen-presenting cells in an MR-dependent manner. In particular, the dectin-1/TLR2 pathway could amplify MR-induced IL-17 production in the absence of mitogenic stimulation [42]. Together with NOD2 and TLR9, MR was suggested to interact with fungal chitin, diminishing inflammation by increasing IL-10 and reducing proinflammatory cytokine production [43]. Recent studies have further supported the role of MR in controlling inflammation. For instance, MR has been shown to induce T-cell reprogramming and subsequent tolerance via inhibition of CD45 and upregulation of the inhibitory molecule CTLA-4, which was responsible for the impaired cytotoxic activity of T cells [44].

**Intracellular Signaling**

MR does not have any defined signaling motif in their cytoplasmic domain, and the ability of MR to induce specific signaling is still controversial. Recent work has shown the important role of the FcRγ chain along with the adaptor protein Grb2 in MR-mediated phagocytosis of *Mycobacterium tuberculosis*. MR interaction with the FcRγ chain was shown to be essential for MR surface expression. In addition, MR activation has been suggested to lead to phosphorylation of its cytoplasmic tyrosine and recruitment of Grb2 followed by activation of the Rac/Pak/Cdc-42 signaling cascade. This in turn leads to SHP-1 recruitment to the phagosome, limiting PI3K activity and phagosome-lysosome fusion [45].

**Role in Antifungal Immunity**

In vivo studies have suggested that MR has a largely redundant role in immunity to most fungal pathogens,
including *C. albicans*. However, mice lacking MR were shown to be more susceptible to *C. neoformans* and experimental blastomycosis. This effect was associated with defective DC maturation and subsequent CD4⁺ T-cell responses [46, 47].

**Additional Mannose-Binding Lectins**

**Galectins**

Galectins are a family of soluble and cell-bound proteins that bind β-galactosides. These proteins are highly conserved and are expressed by diverse cell types, including monocytes, DCs, macrophages, mast cells, B cells and T cells. Galectin-3 contains a CRD preceded by a non lectin region consisting of short Pro/Gly-rich tandem repeats.

**Ligands and Cellular Responses**

It was previously shown that galectin-3 on macrophages recognizes β-mannan from *C. albicans* and, in collaboration with TLR2, is able to induce protective antifungal responses via TNF-α secretion [24]. It has also been suggested that galectin-3 can have a dual role in the regulation of neutrophil function, depending on its cellular location. While recombinant galectin-3 was shown to enhance neutrophil phagocytosis of *C. albicans*, it was also found that intracellular galectin-3 can downregulate neutrophil fungicidal activities by physically interacting with Syk and therefore reducing ROS-dependent killing of *C. albicans* [48].

**Role in Antifungal Immunity**

Mice deficient in galectin-3 have been found to be more susceptible to disseminated candidiasis [24]. More recently, it was also shown to play a role in *C. neoformans* infection, as galectin-3-deficient mice were found to be more susceptible to cryptococcosis than wild-type mice. In addition, galectin-3 was able to inhibit fungal growth and exert a direct lytic effect on *C. neoformans* extracellular vesicles protecting the host from potential fungal virulence factors carried in these vesicles [49].

**Mannose-Binding Lectin**

Mannose-binding lectin (MBL) is a soluble lectin belonging to the collectin family and consists of a CRD that is attached to a collagen region via an α-helical coil domain. It is produced by the liver and secreted into the blood, where, after binding to microbial carbohydrate surfaces, it can activate the lectin pathway of the complement cascade, enhancing the phagocytosis of microorganisms and modulating inflammatory responses. There are 2 MLB isomers in the mouse, i.e., MBL1 and MBL2, while humans only have MBL2.

**Ligands and Cellular Responses**

Fungal binding by MBL triggers a protease cascade though the MBL-associated serine proteases that leads to the activation of the complement pathway (the lectin pathway) and deposition of complement components on the fungal surface. MBL plays an important role in the innate defense against several fungal pathogens, including *C. albicans*. Direct interaction between MBL and mannosylated components of the fungal cell wall results in agglutination as well as complement activation, which can inhibit growth of (but not kill) *Candida*. In addition, during pulmonary inflammation, MBLs can leak into alveoli where they can interact with *A. fumigatus* conidia through D-mannose, L-fucose, and N-acetylglucosamine residues in a Ca²⁺-dependent manner, leading to complement activation. Furthermore, studies utilizing serum obtained from transgenic animals have indicated that only MBL2, and not MBL1, recognizes *A. fumigatus* [50]. MBL can also mediate complement-independent responses, as activation of MBL2 on human neutrophils can control phagocytosis and subsequent ROS production against *Candida*, independently of complement activation, a response thought to be coupled with dectin-1 recruitment and signaling [24].

**Role in Antifungal Immunity**

In a murine model of aspergillosis, administration of recombinant human MBL2 protects mice against infection, while MBL deficiency renders them susceptible. This susceptibility was associated with reduced phagocytosis, complement activation, and cytokine production [50]. MBL1 has also been shown to modulate *Candida* colonization in the gut [51]. Furthermore, in humans, SNPs in MBL2 have been implicated in susceptibility to aspergillosis and candidiasis [52].

**Toll-Like Receptors**

TLRs are type-I integral membrane glycoproteins, each with an extracellular N-terminal ligand recognition domain constructed of tandem copies of a leucine-rich repeat motif that provides ligand specificity, a single
transmembrane helix, and a C-terminal cytoplasmic signaling domain known as Toll IL-1 receptor domain (TIR) (reviewed elsewhere in this series). These receptors homo- or heterodimerize upon ligand binding followed by recruitment and signaling through specific sets of adaptor proteins, including myeloid differentiation primary response 88 (MyD88) and TIR domain-containing adapter-inducer interferon-β (TRIF) [53].

Ligands and Cellular Responses

Intensive research in this area in the last few years has identified several fungal PAMPs recognized by TLRs; however, the primary structures of the fungal ligands have not yet been fully resolved. Some studies have suggested that mannosylated structures derived from Candida, Cryptococcus, and Scedosporium can directly interact with specific TLRs, including TLR1, TLR2, TLR4, and TLR6, triggering inflammatory responses [23]. For instance, O-linked mannosyl residues as well as rhamnomannans from Candida and Scedosporium, respectively, can be recognized by TLR4 leading to the induction of proinflammatory cytokines, such as TNF-α and IL-6, by macrophages. Furthermore, phospholipomannan and glucuronoxylomannan from Candida and Cryptococcus, respectively, have been reported to interact with TLR2/TLR6 and TLR2/TLR1 heterodimers leading to the production of proinflammatory mediators, including TNF-α and nitric oxide, by macrophages [23].

Role in Antifungal Immunity

TLRs were first identified over 2 decades ago by their ability to control fungal infections in Drosophila, which prompted their study in the mammalian host defense against fungal pathogens. Studies have suggested that different TLRs are able to activate specific arms of the antifungal defense mainly in collaboration with CLRs such as dectin-1 and MR. MyD88-deficient mice, which have defective TLR responses from multiple family members, show increased susceptibility to infection with major humoral effector domain, a central NOD involved in oligomerization and a C-terminal leucine-rich repeat domain involved in ligand binding. There are 4 N-terminal domains that define their subfamilies named NLRA, NLRB, NLRC, and NLRP [53]. Originally associated with bacterial recognition, these receptors have also been linked with fungal immunity, mainly through interactions with other PRRs.

Ligands and Cellular Responses

The best characterized NLR in terms of antifungal immunity is NLRP3, which is a component of the inflamma-
some, characterized by the activation of caspase-1 and the subsequent production of IL-1β and IL-18. NLRP3 is expressed by many cells, including macrophages, DCs, T cells, B cells, and epithelial cells. Several yeast cell wall preparations have been shown to activate NLRP3, as well as secreted proteases from *C. albicans* [60]. In vitro studies have shown the importance of NLRP3 in host defense against *A. fumigatus*. For instance, LAP (LC3-associated phagocytosis), a noncanonical form of fungal autophagy, can regulate inflammation by inhibiting NLRP3 activation. Here, *A. fumigatus* was shown to activate IFN-γ-dependent DAPK1, a death-associated protein kinase, which led to fungal autophagy and proteosomal-mediated NLRP3 degradation, limiting pathogenic inflammatory responses [61]. Fungi can also affect this response, such as *C. neoformans*, whose capsule can prevent NLRP3 activation facilitating intracellular survival [6].

*C. albicans* and *C. neoformans* have been shown to activate additional canonical and noncanonical inflammasomes, including NLRCA, NLRP10, and caspase-8 [3, 34]. Activation of dectin-1/Syk/CARD9 signaling upon fungal recognition can activate the noncanonical MALT1/ASC/caspase-8 inflammasome. Whereas the CARD9/Bcl10/MALT1 scaffold directed IL-1β transcription, the recruitment of caspase-8 and the adaptor protein apoptosis-associated speck-like protein containing a CARD domain (ASC) into this scaffold induced the processing of pro-IL-1β into its mature form by caspase-8 [62].

**Role in Antifungal Immunity**

Different components of the inflammasome, including ASC, IL-1R, IL-1β, and caspase-1, have been shown to be involved in antifungal resistance to many pathogens, such as *C. albicans*, *A. fumigatus*, *C. neoformans*, and *Paracoccidioides brasiliensis* [6, 63]. Additionally, mice deficient in NLRP3 have shown susceptibility to several fungal pathogens, including mucosal candidiasis and subsequent disseminated infections [17, 24]. In addition to its role in *Candida* infection, NLRP3 has been suggested to be essential for resistance against *P. brasiliensis* through its role in IL-18-dependent inflammatory responses [64]. NLR4 has also been shown to exert a protective, but tissue-specific, role in oropharyngeal candidiasis. In contrast to NLRP3, NLR4 is only essential in the stromal compartment where it is involved in neutrophil recruitment and control of fungal dissemination [65]. In humans, a SNP in NLRP3 has been associated with susceptibility to mucosal candidiasis due to impaired production of IL-1β [52].

**RIG-Like Receptors**

RLRs are intracellular receptors characterized by the presence of a DExD/H box RNA helicase domain with ATPase activity. They are expressed in both immune and nonimmune cell types and regulate signaling pathways that promote type-I and type-III IFN production, and are traditionally associated with antiviral immunity [53].

**Role in Antifungal Immunity**

DC-derived type-I IFNs have also been shown to play a key role in host responses against *Candida* and *Histoplasma*; however, type-I IFN production upon fungal recognition seems to be dependent on either dectin-1 and/or TLR7/TLR9 signaling pathways [57, 66, 67]. A recent study has shown that type-I and type-III IFNs are critical regulators of the interplay between CCR2+ monocytes and neutrophils, as IFN-α and IFN-λ promote optimal antifungal responses by neutrophils upon *A. fumigatus* challenge [68]. Loss of MDA5, a melanoma differentiation-associated gene and member of the RLR family, has also shown to increase susceptibility to *Candida* infections in mice and humans [69].

**Additional β-Glucan Receptors**

In addition to dectin-1 and CD23, other receptors such as the complement receptor 3 (CR3) and lactosylceramide have been shown to recognize β-glucans. CR3 is an integrin dimer consisting of CD11b and CD18, and is expressed widely by myeloid cells, including monocytes, macrophages, DCs, neutrophils, and natural killer (NK) cells. This phagocytic receptor has a “lectin-like domain” that can bind β-glucan with high affinity, and it has been suggested to be the primary β-glucan receptor on neutrophils and NK cells [70]. However, CR3 predominantly mediates fungal phagocytosis and killing in a complement-dependent manner. It has also been suggested that CR3 together with CR4 (CD11c/CD18) can participate in a complement-independent phagocytosis of *C. neoformans*. This involves opsonization with specific antcapsular IgA and IgM antibodies that changes the structure of the capsule exposing the CD18 binding site in the glucuronoxylomannan [71].

Recent studies have further supported the role of CR3 in antifungal immunity. CR3 binding to fibronectin and β-glucan can initiate a complex mechanism of integrin interactions in neutrophils that results in cellular aggregation and NETosis [72]. In vivo models have shown that...
CR3 helps drive Th1 and Th17 responses during *A. fumigatus* infections and is essential for resistance to infection with *C. albicans* and *C. glabrata* [73, 74].

Scavenger receptors are a family of cell surface glycoproteins that have also been implicated in β-glucan recognition [1]. The macrophage receptor with collagenous structure (MARCO) has been shown to be required against *C. neoformans* infection in a mouse model. MARCO deficiency leads to impaired fungal control, associated with diminished cell recruitment and activation [75]. CD5 is a receptor that belongs to the scavenger-receptor cysteine-rich (SRCR) superfamily and is expressed primarily by B cells and T cells. Intriguingly, it has been shown that a naturally occurring soluble isoform of CD5 can bind to *Schizosaccharomyces pombe*, *C. albicans*, and *C. neoformans* fungal cells and induce their aggregation. It appears that one of the three SRCR repeats present in the CD5 extracellular domain can bind β-glucans, which might subsequently attenuate the immune response to systemic fungal challenge [76]. Using a mouse model, the scavenger receptors SCARF1 and CD36 have been shown to mediate cytokine production and host defense against *C. neoformans* in a β-glucan dependent manner by functioning as coreceptors to facilitate TLR2 signaling [77]. Finally, recent work has identified the receptor tyrosine kinase ephrin type-A receptor 2 (EphA2) as a β-glucan receptor in oral epithelial cells that is critical for mediating protective immunity during oral candidiasis. Binding of EphA2 to *C. albicans* activates STAT3 and MAPK signaling pathways required to induce proinflammatory cytokines, such as IL-17, to control fungal dissemination in a mouse model of oropharyngeal candidiasis [78].

**PRR Crosstalk**

Encounter with pathogens can lead to the simultaneous engagement of several PRRs, and the signals emanating from these different receptors are integrated to induce appropriate biological responses. Although this is still a poorly understood area, there have been significant advances in the last decade (Fig. 2). One discovery, for example, is that different receptors can form heterodimers. There is strong evidence showing that MCL can dimerize with related CLR members to regulate their levels of expression, expand ligand specificity, and amplify signaling. For instance, MCL can constitutively form heterodimers with dectin-2, which, compared to their respective homodimers, bind α-mannans more efficiently leading to potent Syk-dependent proinflammatory responses upon *C. albicans* infection [29]. In addition, MCLs have been shown to positively regulate Mincle gene expression through ligand binding as well as protein expression, through protein–protein interaction via its stalk region, thereby magnifying Mincle-mediated signaling [30]. There have also been many studies describing synergistic or antagonistic intracellular signaling between PRR in antifungal immunity. Through association with lipid rafts, dectin-1 and CR3, for example, can collaboratively trigger macrophage IL-6 and TNF-α production via the Syk-JNK pathway and subsequently induce host defense against disseminated histoplasmosis [79]. More recently, it has been suggested that dectin-1 can also interact with dectin-2 and trigger the Syk-JNK pathway to activate the NLRP3 inflammasome in response to *H. capsulatum* [80].

Following fungal recognition, collaboration between CLR and TLRs has also been shown to be pivotal in antifungal immunity, and this crosstalk has been particularly evident in the case of the fungus *F. pedrosoi*, an etiologic agent of chromoblastomycosis. This chronic infection of the skin and subcutaneous tissues was shown to result from inadequate innate fungal recognition by CLR, primarily Mincle, which resulted in a defective inflammatory response. Using a murine model, it was shown that clearance of *F. pedrosoi* infection could be facilitated following cooperative stimulation of the TLR signaling pathway, an approach that was also shown to be effective in treating the disease in humans [81]. Moreover, recognition of this fungus by Mincle could suppress dectin-1- and dectin-2-induced T-cell responses [28]. This antagonistic role of Mincle over other PRR has also been observed in other contexts, such as with TLR4 and NLRP3 [82]. Other interactions between CLR and TLRs have also been described, including dectin-1 and TLR2 crosstalk in the recognition and phagocytosis of zymosan, and their ability to synergize in the activation of NF-κB and subsequent cytokine production (Fig. 2) [27].

It is important to mention that there is also evidence suggesting that NLRs could interact with other PRR members, including TLRs. For instance, fungal chitin, through MR, NOD2, and TLR9 activation, can diminish inflammation by increasing IL-10 and reducing proinflammatory cytokine production, as described above [43]. Moreover, it has been shown that IFN-β induced by *Candida parapsilosis* can inhibit fungal clearance by signaling through STAT1/2 to induce IL-27 in a TLR7- and NOD2-dependent manner. Therefore, inhibition of IL-27 could be a potential avenue for therapy in this disease, but further studies are needed [83].
Fig. 2. Crosstalk between different PRRs in antifungal immunity. Dectin-2 and MCL can form heterodimers and amplify proinflammatory cytokine production upon *Candida* infection. Dectin-1 and dectin-2 can synergize to induce the NLRP3 inflammasome against *Histoplasma capsulatum* challenge. In addition, dectin-1 and CR3 can collaboratively trigger proinflammatory cytokine production against histoplasmosis. *Fonsecaea pedrosoi* activates the Mincle signaling pathway but requires costimulation with TLR ligands to induce protective immunity. Mincle can also antagonize dectin-1 signaling upon recognition of *F. pedrosoi*. Finally, dectin-1 and TLR2 interact in the recognition and phagocytosis of zymosan particles leading to proinflammatory cytokine production. Activatory signals are in blue, inhibitory signals are in red.
Innate Cellular Components

Surveillance and elimination of fungal pathogens relies on the sentinel behavior of several cells of the innate immune system and the recruitment of effector cells. Defects in antifungal effector functions of these cells result in susceptibility to many fungal pathogens, including C. albicans and A. fumigatus. Activation and differentiation of specific T-cell subsets is also a pivotal process, required for the control of systemic fungal infections with pathogens, including Cryptococcus and Pneumocystis, and protection against mucocutaneous infections. Indeed, the roles of Th1 and Th17 cells, respectively, have been well established in this context [6, 84]. Th1-type cytokines stimulate the effector function of phagocytes, while Th17-related cytokines, such as IL-17 and IL-22, promote the release of antimicrobial peptides by mucosal epithelial cells and induce neutrophil recruitment and activation [6, 17, 84–86]. The role of other adaptive immune cells, such as B cells, is less clear and has been reviewed elsewhere [23, 87]. Here, we are going to focus on recent advances in our understanding of the pivotal role of innate immune cells, including granulocytes, monocytes, macrophages, DCs, and innate lymphoid cells, in antifungal immunity (Fig. 3).

Granulocytes

Neutrophils are the most important innate immune effector cells for the control of many fungal infections. Their importance in fungal infections was originally demonstrated in humans suffering from neutropenia that exhibited a dramatic increase in susceptibility to major fungal pathogens, including C. albicans and A. fumigatus. Moreover, mutations associated with various aspects of neutrophil recruitment and antimicrobial activity, including CXCR1, NADPH oxidase, and myeloperoxidase, are strongly associated with an increased risk of systemic fungal infections in humans [87]. Neutrophils use oxidative and nonoxidative killing mechanisms against fungal pathogens (Fig. 3). Oxidative mechanisms include ROS production, mediated by the enzymes NADPH oxidase and myeloperoxidase, while nonoxidative mechanisms include the release of granules containing proteins with antimicrobial and degradative properties, including defensins, lysozyme, lactoferrin, gelatinases, elastase and cathepsin-G [41, 88]. NADPH oxidase deficiency results in chronic granulomatous disease, which is associated with increased susceptibility to invasive mold infections [17]. Interestingly, the jagunal homologue 1 (JAGN1) protein has been recently established to be an important factor for survival and differentiation of neutrophils in fungal host defense. Mice deficient in JAGN1 could not mount an efficient neutrophil-dependent immune response against C. albicans, characterized by defective migration and impaired formation of cytotoxic granules [89]. Furthermore, C5a receptor signaling in human neutrophils has been linked to the regulation of killing mechanisms during Candida infection [90].

Neutrophils also produce NETs against fungi that are too big to be phagocytosed. Originally described in 2004 as a killing mechanism against bacterial infection, NETs are large fibrillar structures composed of DNA, histones, and antimicrobial peptides that bind extracellular pathogens preventing them from spreading and ensuring a high concentration of antimicrobials [91]. NETs have been shown to be induced by several fungi, including C. albicans, A. fumigatus, and C. neoformans [17]. Calprotectin, a key component of NETs, was shown to control the growth of Candida and Aspergillus, and mice deficient in calprotectin are more susceptible to infection [92]. Additional methods of killing by neutrophils include a ROS-independent mechanism of killing against Candida that relies on CR3 ligation and the activation of the PI3K and CARD9 signaling pathways [93] and a mechanism that involves induction of fungal apoptosis [94]. In the latter, the engulfment of A. fumigatus spores by neutrophils was shown to induce a programmed cell death response in the fungus, induced by the phagocyte NADPH oxidase and fungal caspases [94].

IL-17 is a potent mediator of neutrophil recruitment, and in addition to lymphocytes, neutrophils have also been proposed to be a source of IL-17, which acts in an autocrine manner to induce further neutrophil recruitment to the site of infection [95]. However, the extent to which IL-17 can control neutrophil function is unclear, since some in vivo studies have suggested that absence of IL-17 does not result in complete neutrophil dysfunction, and their recruitment is not entirely dependent on IL-17 [96]. This suggests that additional IL-17-independent signals can contribute to neutrophil recruitment. For instance, NK cell-derived GM-CSF was shown to be essential for the fungicidal activity of neutrophils. GM-CSF production by NK cells and subsequent activation of neutrophils was orchestrated by DCs through IL-23 production [97]. In addition, IL-15 production by monocytes was shown to drive efficient activation and GM-CSF release from NK cells, which was necessary to boost the killing potential of neutrophils against Candida [98].
Despite their crucial role, excessive neutrophil activation and/or recruitment can also be harmful. For example, increased neutrophil recruitment into the kidney amplifies late renal immunopathology and increases mortality in a model of invasive candidiasis [99]. This demonstrates that excess inflammation can be detrimental to the host, causing tissue damage and contributing to the pathogenesis of the disease. In an attempt to better describe the disease origins and progress, this and other concepts were incorporated in the damage-response framework by Pirofski and Casadevall [100]. This idea states that the disease-causing potential of a microbe is determined by the immune state of the host, and that the outcome of the interaction between host and pathogen is dependent on the amount of damage to the host, which can be a result of microbial factors and/or the host response [100].

Other granulocytes such as mast cells, basophils, and eosinophils have been implicated in allergic fungal diseases. For instance, due to their strategic location in the lung, mast cells can readily interact with invading fungi,
including *A. fumigatus*, which induces their degranulation, the secretion of granular proteins and cytokines, and fungal killing [101]. In addition, eosinophil protease-activated receptor 2 (PAR2) is cleaved by aspartate proteases produced by *Alternaria alternata*, exposing neoligands that activate eosinophils causing their degranulation and release of cytotoxic granule proteins and chemokines in the lung [102]. IgE binding to *A. fumigatus*-derived allergens can crosslink FcεR on the surface of basophils inducing their degranulation and histamine release leading to asthma exacerbation [103]. However, more studies are needed to fully decipher how these cell types interact with fungi and their role in antifungal immunity outside the lung.

**Mononuclear Phagocytes**

Besides neutrophils, mononuclear phagocytes are now being increasingly recognized as critical mediators of host defense against fungi. Several studies have focused on understanding the mechanisms by which resident and recruited monocytes, macrophages, and DCs accumulate and become activated at the sites of fungal infection. Tissue resident macrophages as well as monocyte-derived macrophages have been revealed to be key effector cells in controlling fungal infections through the direct killing of fungi and the production of proinflammatory cytokines and chemokines that can recruit and activate other immune cells in peripheral organs (Fig. 3) [6, 17].

**Macrophages**

The importance of macrophages in antifungal immunity was first shown over 20 years ago, in which in vivo depletion of macrophages increased susceptibility to disseminated candidiasis [6, 17]. This has been further supported by recent studies showing that deficiency in the chemokine receptor CX3CR1, which is associated with impaired recruitment of monocyte-derived macrophages into tissues, increased fungal growth and mortality after *Candida* challenge. In fact, patients with a polymorphism leading to decreased function of CX3CR1 also exhibit increased susceptibility to systemic candidiasis [104]. Macrophage switching between M1/M2 phenotypes has also been shown to be crucial in the protection against diverse fungal pathogens, including *C. albicans*, *C. neoformans*, *H. capsulatum*, and *P. brasiliensis*. For instance, type II cytokines, such as IL-4, impair host defense against *H. capsu-
a model of lung infection with *P. brasiliensis* [113]. *P. brasiliensis* infection, for example, increased the number of pDCs expressing indoleamine 2,3-dioxygenase (IDO), an enzyme with immunoregulatory properties that drives regulatory T cell (T<sub>reg</sub>) expansion [113]. Remarkably, dectin-1-mediated activation of pDCs has been suggested to promote Th2 responses, while dectin-1 activation on myeloid DCs decrease Th2 responses upon β-glucan challenge. This cell-specific effect was associated with their distinct abilities to control ox40L surface expression [114]. It is also interesting to mention that dectin-2-mediated *A. fumigatus* recognition by pDCs induces pro-inflammatory cytokine production and the formation of pDC extracellular traps [115].

Specific DC subsets have also been shown to act in a complementary fashion during fungal infections to induce appropriate T-cell responses. For instance, tissue-resident FIt3L-dependent DCs and CCR2-dependent monocyte-derived DCs can collaborate in antigen presentation and T-cell priming during mucosal candidiasis, while Langerhans cells appear not to be required for this response [116]. Monocyte-derived DCs also have a pivotal role in inducing CD4+ T-cell responses against *Aspergillus* infection in the lung. TNF-α from monocyte-derived DCs induces neutrophilia versus eosinophilia during persistent fungal infection in the airways by modulating the balance between IL-17 and IL-5 production [117].

The ability of DC to shape the type of effector T-cell responses depends on several factors, including the nature of fungal organisms, the site of infection, and host susceptibility. For instance, skin-resident DC subsets promote distinct and opposing antigen-specific T-helper responses. Using a *C. albicans* infection model, Kaplan et al. [118] have shown that Langerhans cells are necessary and sufficient for the generation of Th17 cells, while Langerin+ dermal DCs are required for the generation of antigen-specific cytotoxic lymphocytes and Th1 cells, and also inhibited the ability of Langerhans cells to promote Th17 responses. Fungal morphology can also determine T-helper cell differentiation. Yeast forms of *C. albicans* can induce Th17 responses through dectin-1 interaction on Langerhans cells and subsequent IL-6 production. Conversely, filamentous forms induced Th1 responses due to the absence of dectin-1 ligation [119]. Furthermore, the Kaplan group has shown that nociceptor sensory fibers drive IL-23 production in dermal DC, leading to the induction of IL-17 by dermal γδ T cells and subsequent activation of neutrophil antimicrobial activity, and conferring protection against *C. albicans* cutaneous infections [120].

### Innate Lymphocytes

Innate lymphoid cells (ILCs) are the most recently identified population of immune cells that have been implicated in antifungal immunity. Three types of ILCs have been defined and characterized by their cytokine profile and transcription factor expression, ILC1 or Th1-like, ILC2 or Th2-like, and ILC3 or Th17-like cells. ILC3 or group 3 ILCs are characterized by their production of Th17 cytokines, including IL-17 and IL-22. IL-17-producing ILC3 cells were demonstrated to play an essential role in mucosal candidiasis [121, 122]. Additionally, it has been shown that *Candida*-mediated protection against *P. aeruginosa*-induced lung injury was dependent on pulmonary ILCs expressing IL-22 (Fig. 3) [123]. ILC2 or group 2 ILCs produce Th2 cytokines and have shown to exert a negative antifungal effect in mouse models and humans. For instance, IL-33-producing ILC2 cells were shown to have a detrimental role in pulmonary immunity against *C. neoformans* [124] and in patients with severe asthma associated with fungal sensitization [125]. Similar detrimental roles of IL-13-producing ILC2s were demonstrated in a mouse model of *C. neoformans*-induced airway inflammation [126] and in patients with *Aspergillus*-mediated chronic sinusitis [127]. Interestingly, prostaglandin I2 can reduce the number of Th2-expressing ILC2 in the lung, such as IL-13 and IL-5, and could potentially be exploited as a therapeutic strategy in this context [128].

NK cells represent the prototypical member of the ILC family. Together with ILC1, NK cells constitute group 1 ILCs, which are characterized by their capacity to produce IFN-γ. NK cell activation leads to direct killing of diverse fungal pathogens via the release of extracellular perforin (Fig. 3). Perforin-dependent microbicidal activity against *C. neoformans* requires PI3K-dependent ERK1/2 signaling on NK cells [129]. These cells can also produce GM-CSF necessary for the fungicidal activity of neutrophils, described above [97]. In the past, studies using NK cell-depleted mice have revealed their critical role in the control of infections with several fungal pathogens, including *C. neoformans*, *H. capsulatum*, *C. albicans*, and *A. fumigatus* amongst others [17, 24].

Recent studies have been focused on the mechanisms underlying the recognition of fungi by NK cells. The NKP30 receptor has been shown to be responsible for recognition of *C. albicans* and *C. neoformans*, and subsequent killing through perforin release [130], and the human NKP46 receptor and its mouse ortholog, NCR1, were reported to bind *C. glabrata* and mediate fungal...
Epithelial Cells and Barrier Tissues

A decade ago, we were just beginning to appreciate the role of epithelial cells in homeostasis and immunity. We now know that epithelial cells not only act as a physical barrier against pathogens, allergens, and foreign substances, but that they also constitute the first line of defense through the expression of a wide range of PRRs, including CLRs, TLRs, and PARs. TLRs are widely expressed by epithelial cells, while the expression of CLRs is less well defined. Studies have suggested that MRs appear to be extensively expressed on epithelial cells in diverse tissues, and that dectin-1 can be induced on epithelial cells after microbial encounter. PARs are G-protein-coupled receptors expressed on airway epithelial cells characterized by a self-activation mechanism following cleavage by fungal-derived proteolytic allergens. Fungal-induced endocytosis by oral epithelial cells was shown to be mediated by E-cadherin and aryl-hydrocarbon receptor (AhR)/Src/EGFR/HER2 receptor tyrosine kinase signaling, inducing rearrangement of epithelial cell microfilaments, leading to the formation of pseudopods that engulf the fungus. Treatment with either a dual kinase inhibitor or an AhR inhibitor significantly reduced the severity of oropharyngeal candidiasis in mice [135, 136]. Furthermore, the receptor tyrosine kinase EphA2 was identified as a β-glucan receptor in oral epithelial cells involved in the control of fungal dissemination, as described above [78].

In addition to their ability to directly recognize fungi, epithelial cells can also participate in fungal phagocytosis and the production of inflammatory alarmins, chemokines, and cytokines [17, 24]. For instance, epithelial cells produce mucins and antimicrobial peptides, such as β-defensin and cathelicidin, which can repress tissue invasion and display direct fungicidal activities [137]. These proteins have also effects on bacterial components of the microflora [138]. Interestingly, the fungal germination process can be seen as a danger signal by epithelial cells since they can discriminate between commensal yeast and pathogenic hyphal forms of C. albicans, responding via an NF-κB and a biphasic MAPK signaling pathway, highlighting the importance of epithelial cells in maintaining commensal populations [139]. In addition, fungal-derived toxins, such as the recently described candidasins, can damage epithelial membranes and trigger a danger response signaling pathway that activates epithelial immunity [140].

Along with epithelial cells, endothelial cells are also key responders during fungal invasion. During mucormycosis, an infection that primarily affects patients with diabetic ketoacidosis, the endothelial receptor glucose-regulated protein 78 (GRP78) binds Rhizopus oryzae promoting cell invasion via fungal coat protein homologue 3 (CotH3) [141]. Moreover, metabolic changes associated with hyperglycemia and diabetic ketoacidosis...
increased the expression of GRP78 on endothelial cells promoting fungal invasion. Interestingly, antibodies directed against GRP78 or CotH3 protect mice from mucormycosis, which could be exploited as a therapeutic strategy [142]. C. albicans can also interact with endothelial cells and induce its endocytosis by an interaction between fungal-derived invasins and a complex containing N-cadherin, present on the endothelial cell surface, as well as septin 7. Septin 7 is a GTP-binding protein that can interact with endothelial cell microfilaments, thereby inducing microbial endocytosis, a mechanism that is likely to be relevant to host cell invasion by other microbial pathogens [143].

**Mycobiome**

In the last few years, interactions between the immune system and the mycobiome are being recognized as important for immune homeostasis and as a cause of pathology during disease. This is particularly evident at the mucosal surfaces, where many immune and nonimmune cells are not only important in surveillance, but also in maintaining commensal relationships and protection from invasion. The diversity of the microbiome on human skin is an area of intense investigation because changes in its composition are associated with the development of chronicity of many dermatological conditions and diseases. For instance, Malassezia species have been associated with exacerbating various skin conditions, such as psoriasis, eczema, and dermatitis, in which barrier functions are compromised [144]. In addition, skin sensitization to C. albicans is strongly correlated with the development of dermatitis, and C. albicans morphology and specific skin-resident DC subsets can determine T-helper-cell differentiation in the skin, as described above [118, 119]. Interestingly, a recent longitudinal metagenomic study revealed that despite the exposure of the skin to the external environment, its microbial communities, including fungi, were largely stable over time, suggesting that any changes in these interactions reflect disease states [145].

Little is known about the fungal microbiota of the respiratory tract. One of the most comprehensive studies analyzed the mycobiome of the mouth. In this study, it was found that the distribution of the fungal species in the mouth varied greatly between different individuals, including species of Candida, Aspergillus, Fusarium, and Cryptococcus amongst others. Of note, noncultivable fungi represent almost 40% of the fungi identified [146]. Another study shows that fungal communities in the lung of patients receiving lung transplants differ in structure and composition from healthy subjects, which could be a consequence of antibiotics and/or immunosuppressant treatment [147].

Inhalation of fungal spores results in sensitization and exacerbation of allergy and asthma, and specific fungal species have been associated with the development of airway conditions. Pneumocystis, for example, has been implicated in a number of chronic pulmonary inflammatory diseases, including pneumonia. Fungi can also directly interact with lung cells inducing antifungal and proinflammatory mechanisms. For instance, fungal-derived proteolytic allergens can activate PARs leading to an increase in lung epithelial permeability and the release of proinflammatory cytokines [148]. In addition, dectin-1 recognition of A. fumigatus in the lung was recently shown to enhance fungal allergy through IL-22 secretion [149].

The most common fungal pathogen colonizing the genital-urinary tract is C. albicans, which can become pathogenic in some individuals causing recurrent infections. Recent studies have shed some light on mechanisms conferring enhanced susceptibility to recurrent vulvovaginal candidiasis (VVC). For instance, S100 alarmin proteins have been shown to mediate immunopathogenic responses in susceptible patients, as epithelial cell-derived S100 alarmins induced by C. albicans are sufficient to induce acute neutrophil responses during experimental vaginal candidiasis [150]. Furthermore, protection against VVC was shown to be dependent on IL-22 and the enzyme IDO, as mice deficient in either IDO or IL-22 were more susceptible to VVC. Of note, replacement therapy with kynurenines restored immune protection to VVC, which suggests a potential therapy for these patients [151].

The mammalian gut contains a rich fungal community that accounts for around 0.1% of the genes in the fecal microbiota. Similar to the genitourinary tract, C. albicans is the most common commensal fungus [152]. Dysregulation in levels of colonization with this organism has been associated with enhanced severity in several conditions, including gastric ulcers, allergic sensitization to food allergens, ulcerative colitis, and Crohn disease, and has also been linked with susceptibility to systemic candidiasis. Interactions between commensal fungi and CLRIs, such as dectin-1 and SIGNR3, have been shown to influence colitis, and the loss of these receptors has been suggested to affect fungal recognition as well as barrier integrity [22, 40]. It was shown, for example, that the absence of dectin-1 on DCs can significantly affect the de-
development of CD4+ T-cell responses to *Candida* infection in the GI tract [153]. Others have suggested that inhibition of dectin-1 signaling can ameliorate colitis, by decreasing antimicrobial peptide production, inducing *Lactobacillus* overgrowth and Treg expansion [154]. SIGNR3 has been implicated in sensing fungi present in the microbiota, influencing inflammation in the colon; SIGNR3-deficient mice exhibited more severe colitis symptoms than wild-type controls [40]. In an experimental model of colitis, it was also shown that MBL1/2-deficient mice had higher levels of *C. albicans* colonization than wild-type littermates, which was associated with elevated expression of proinflammatory cytokines [51]. Finally, MCL-deficient mice have been shown to be more susceptible to dextran sodium sulfate-induced colitis and exhibited increased *Candida tropicalis* burden, which correlates with impaired phagocytic and fungicidal abilities of macrophages [155].

In the gut, several subsets of phagocytes can respond to fungal infection as well as to fluctuations in resident fungal communities. Among these, mononuclear phagocytes expressing CX3CR1 and DCs expressing the integrins CD103 CD11b have been shown to be pivotal in inducing immune responses against microbes in the gut. However, there is some controversy regarding which cells are essential for initiating antifungal immune responses in the gut. IRF4-dependent CD103+ CD11b+ DCs, in particular, are central in intestinal Th17 differentiation and Th17-induced fungal clearance [156, 157]. Intestinal CD103+ DCs were shown to serve as classical DCs in antigen sampling and initiation of adaptive immune responses in gut lymph nodes, while CX3CR1+ populations were suggested to modulate immune responses directly at the mucosal sites and serve as first-line barrier against invading pathogens [158]. In addition, CD103+ CD11b–DCs can restrain colitis by inducing an anti-inflammatory response by epithelial cells that is dependent on IDO [159]. In fact, CD103+ DCs can also express IDO themselves, influencing the balance between Treg/T-effector cells and induction of tolerance that would protect mice from colitis [160]. Furthermore, CX3CR1+ cells have been shown to directly transfer antigens to CD103+ DCs via gap junctions to induce tolerance [161]. A recent study has identified that CX3CR1+ mononuclear phagocytes are essential for the initiation of innate and adaptive immune responses to intestinal fungi in the colon and mesenteric lymph nodes but not the small intestine, and genetic ablation of CX3CR1+ cells in mice led to changes in gut fungal communities and the development of severe colitis [162].

Interaction between *Candida* and bacterial components of the microbiota has also been shown to shape immune responses in the GI tract. These bacterial communities can prevent high-level fungal colonization and disease, as germ-free mice, lacking natural microbiota, are highly susceptible to *Candida* colonization. In vitro studies have shown that bacterial components can block yeast adhesion to the epithelium and produce metabolites that reduce hyphal transformation and invasion. Alterations in the abundance of *Lactobacillus* strains, as observed in CARD9-deficient mice, make these animals more susceptible to colitis as their microbiota fail to metabolize tryptophan into the metabolites that act as AhR ligands [163]. CARD9 SNPs in humans have also been associated with increased susceptibility to colitis [164]. Furthermore, similar to studies using deficient mice, humans with an SNP in dectin-1 were associated with more severe forms of colitis [22].

**Therapeutic Approaches**

As eukaryotes, fungi are very similar to mammalian cells, significantly complicating drug development and therapeutic approaches to combat fungal disease. However, advances in our understanding of the interplay between fungi and the host have led to the exploration and design of innovative immunotherapeutic approaches. Initial therapeutic strategies were focused on the use of recombinant cytokines. For instance, colony-stimulating factors, such as GM-CSF and G-CSF, designed to increase the number of myeloid cells and induce neutrophil activation, have been used with varied success. IFN-γ therapy, intended to activate phagocytes and restore defects in Th1 immunity, has proven to be beneficial as an adjunctive therapy in patients with chronic granulomatous disease and cryptococcal meningitis, and in the clearance of fungal disease in transplantation and sepsis patients [165, 166]. Monoclonal antibodies have also been used in immunotherapy. For instance, in murine models, monoclonal antibodies against cell wall β-glucan and *C. neoformans* capsule have proven to be beneficial by inducing opsonization and modulating fungal growth and metabolism [167, 168]. Furthermore, patients with AIDS and cryptococcal meningitis treated with the antcapsular monoclonal antibody show no severe side effects and transient reduction in serum fungal antigen titers [169]. However, more studies are needed to demonstrate their efficacy.

Cellular immunotherapy is a promising approach to treat fungal infections. Adoptive transfer of anti-*Aspergili*
lus T cells has been shown to improve survival following hematopoietic transplantation [170]. In addition, re-engineered T cells expressing a chimeric antigen receptor that recapitulates the specificity of dectin-1 were effective against A. fumigatus in an experimental model [171]. Furthermore, innate cell therapy has steadily gathered pace as a promising alternative approach. For instance, DC pulsed with Aspergillus conidia or transfected with conidial RNA promote antigen-specific Th1-dependent antifungal resistance in mice, which are otherwise susceptible to invasive aspergillosis [172]. Most DC-based research for fungal immunotherapy is preclinical, but there are some exciting studies in patients with hematopoietic transplantation. After receiving adoptive therapy with Aspergillus-specific T-cell clones, for example, patients exhibited high-frequency T-cell responses to Aspergillus and high IFN-γ/IL-10 levels [170].

Vaccination of immunocompromised individuals, a group major risk for developing fungal infections, has also been a challenge regarding efficacy and safety, as they are unable to mount effective and strong immune responses. Therefore, in immunocompromised patients, vaccination should be targeted at the components of the immune system that are relatively intact [165]. Preclinical studies of vaccines containing attenuated fungi have shown promising results; however, they have the additional challenge of using fungi that are sufficiently attenuated so as not to cause disease. As an alternative, vaccines that employ killed whole organisms or purified antigens (subunit vaccines) are intrinsically safer, but they do not tend to elicit robust immune response. Thus, there is an increasing need to develop new adjuvants and delivery systems that can boost innate immune responses to subunit vaccines by targeting antigens to DCs, resulting in enhanced protection. In this context, chitosan, a polycationic homopolymer of glucosamine manufactured by the deacetylation of chitin, is being studied as an adjuvant in DNA- and protein-based vaccines. This polymer has been approved by the United States Food and Drug Administration and appears to be promising in mucosal vaccines.

Currently, there are no fungal vaccines available in clinical practice; however, there are some exciting studies in recent years using fungal components of the cell wall [173]. For instance, a glycoconjugate vaccine composed of β-glucan, laminarin, and the diphtheria toxoid can mount a strong immune response and confer protection against infection with Candida or Aspergillus in mice [167]. In addition, subcutaneous vaccination with glucan particles containing Cryptococcus alkaline extracts can protect mice against cryptococcosis due to the induction of robust Th1 and Th17 immunity [174]. More recently, 2 subunit vaccines containing recombinant C. albicans-derived proteins were found to confer immunogenicity in phase I clinical trials, and they are currently the most promising candidates for a human vaccine [175, 176].

Concluding Remarks

In the last few years, we have seen significant advances in our understanding of antifungal immunity; however, there are still many questions to be answered. For example, we still have very limited knowledge about the interplay between microbial dysbiosis and immunity, and the impact of lifestyle and environmental factors such as diet, physical activity, hygiene, and exposure to xenobiotics on our ability to control infections or impact on the mycobiota. Our challenges in the forthcoming years will be to continue translating the advances we make into the development of novel strategies to combat fungal infections.

Acknowledgments

We apologize to our many colleagues whose valuable contributions we were not able to cite due to space constrains.

Disclosure Statement

Funding was provided by the Wellcome Trust (102705, 097377) and the MRC Centre for Medical Mycology and the University of Aberdeen (MR/N006364/1). F. Salazar holds a postdoctoral fellowship from the National Commission for Scientific and Technological Research (CONICYT), Chile. There are no additional conflicts of interest to declare.

References


13 Wang TT, Tang B, Jiang YY, Xu JF, Lin X, Jia X: E3 ubiquitin ligase Cbl-b negatively reg-


Antifungal Innate Immunity


71 Taborda CP, Casadevall A: CR3 (CD11b/325
72 Johnson CM, O'Brien XM, Byrd AS, Parisi
77 Means TK, Molyanik E, Tampakakis E, Col-
Antifungal Innate Immunity


Antifungal Innate Immunity


